Analyte | Cmaxa (%CV) | tmaxb (Range) | AUC(0-t)a (%CV) | AUC(0-∞)a (%CV) | t1/2a (%CV) |
---|---|---|---|---|---|
ng/ml | h | h · ng/ml | h · ng/ml | h | |
Blood radioactivity | 8344 (25) | 1.00 (0.75–3.00) | 33,395 (15) | 37,093 (16) | 5.90 (43) |
Plasma radioactivity | 13,105 (24) | 0.88 (0.75–3.00) | 55,899 (14) | 60,966 (14) | 6.57 (30) |
Remogliflozin etabonate | 39.0 (113) | 0.50 (0.25–1.50) | 25.8 (58) | 31.1 (47) | 0.39 (42) |
Remogliflozin | 1536 (53) | 0.64 (0.50–2.00) | 2586 (19) | 2595 (18) | 1.57 (9) |
GSK279782 | 607 (28) | 1.00 (0.75–2.00) | 1482 (17) | 1494 (16) | 2.68 (10) |
GSK333081 | 143 (22) | 1.00 (0.75–2.00) | 317 (19) | 323 (19) | 2.84 (12) |
↵a Geometric mean. Eight healthy male volunteers received a single 400-mg dose of [14C]remogliflozin etabonate [mean, 402 ± 1.0 mg (106 ± 0.3 μCi)] by mouth administered as three capsules. The mean percentage of the AUC(0-∞) extrapolated for total radioactivity and individual analytes was equal to or lower than 10%.
↵b Median.